Relapsed/Refractory Blood Cancers
Relapsed/refractory hematologic malignancies are types of blood cancers that either return after treatment or do not respond to initial therapies, affecting the blood, bone marrow, and lymphatic system.
Blood Cancers: Trichostatin A Dose Study
We are exploring the highest safe dose of Trichostatin A for individuals with relapsed or refractory blood cancers. This study aims to ensure the treatment can be tolerated by patients.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej
Oddział Onkologii Klinicznej
Biała Podlaska, Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie
Oddział Kliniczny Hematologii
Grzegórzki, Poland
Pratia Hematologia Sp. z o.o.
Katowice, Poland
Sponsor: Vanda Pharmaceuticals Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.